Troponin I-Interacting Protein Kinase
– A Novel Cardiac-Specific Kinase, Emerging as a Molecular Target for the Treatment of Cardiac Disease –
Hind Lal, PhD; Firdos Ahmad, PhD; Shan Parikh, MSc; Thomas Force, MD

Coronary artery disease is the leading cause of death and disability worldwide. In patients with acute coronary syndromes, timely and effective myocardial reperfusion by percutaneous coronary intervention is the primary treatment of choice to minimize the ischemic injury and limit the size of the myocardial infarction (MI). However, reperfusion can itself promote cardiomyocyte death, which leads to cardiac dysfunction via reperfusion injury. The molecular mechanisms of ischemia-reperfusion (IR) injury are not completely understood and new drug targets are needed.

Recently, we reported that cardiac troponin I-interacting protein kinase (TNNI3K), a cardiomyocyte-specific kinase, promotes IR injury via profound oxidative stress, thereby promoting cardiomyocyte death. By using novel genetic animal models and newly developed small-molecule TNNI3K inhibitors, we demonstrated that TNNI3K-mediated IR injury occurs through impaired mitochondrial function and is in part dependent on p38 MAPK. Here we discuss the emerging role of TNNI3K as a promising new drug target to limit IR-induced myocardial injury. We will also examine the underlying mechanisms that drive the profoundly reduced infarct size in mice in which TNNI3K is specifically deleted in cardiomyocytes. Because TNNI3K is a cardiac-specific kinase, it could be an ideal molecular target, as inhibiting it would have little or no effect on other organ systems, a serious problem associated with the use of kinase inhibitors targeting kinases that are more widely expressed. (Circ J 2014; 78: 1514–1519)

Key Words: Acute coronary syndrome; Acute myocardial infarction; Ischemic heart disease; Reperfusion

Acute myocardial infarction (AMI), with subsequent left ventricular dysfunction and heart failure, continues to be a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of AMI, mainly through timely reperfusion, have substantially improved outcomes but at the same time causing cardiomyocyte death and cardiac dysfunction via reperfusion injury. A number of preclinical and clinical studies have been published on various pharmacological agents to prevent myocardial cell death during the ischemia and subsequent reperfusion. Many of these agents have failed in the translational phase largely because they were ineffective or they produced adverse side effects related to both on- or off-target toxicity in various organs. Because most kinases are ubiquitously expressed, it is not surprising that their systemic administration leads to harmful on-target side effects. Given the fact that localized delivery or gene therapy is still relatively far from clinical reality, it would be a significant step forward if we could identify a cardiac-specific drug target with the ability to limit infarct size and ischemia-reperfusion (IR)-mediated injury post AMI.

Recently, we reported that inhibition of troponin I-interacting protein kinase (TNNI3K), a cardiomyocyte-specific kinase, limited oxidative stress, infarct size and adverse ventricular remodeling post-MI, suggesting that this could be an attractive cardiac-specific therapeutic target for AMI. Studies to test this hypothesis are ongoing. More recent evidence suggests that TNNI3K may have a vital role in several important aspects of cardiac biology, including viral myocarditis, cardiac conduction, cardiomyopathy, obesity and metabolic disorders, and pathological and physiological hypertrophy (Figure 1). However, most of these observations were either made with transgenic mouse models (gain of function) or from large-scale genetic screens (Table). Thus, we need further studies employing loss-of-function strategies (knock-out [KO] and pharmacological inhibition). Here, we review the current findings regarding the role of TNNI3K in different aspects of cardiac biology. We also discuss how the inhibition of TNNI3K is proposed to ameliorate many facets of cardiac injury and metabolic function.

Cloning and Characterization of TNNI3K
TNNI3K was initially cloned in 2003 by investigators at Peking University Union Medical College in Beijing. They...
identified the kinase via a bioinformatics approach and found that it was highly expressed in the heart but not expressed in any other tissues. Subsequently, the full-length TNNI3K mouse mRNA sequence was cloned, and the basal promoter regions were characterized (GenBank accession no. NM015978).10,13

Multiple fetal and adult northern blot experiments, as well as gene arrays, confirmed the cardiac-specific expression of TNNI3K.6,10 Within the heart, TNNI3K is variably expressed in all regions, with the highest levels in the interventricular septum and apex. Immunohistochemical analysis detected TNNI3K predominantly localized to perinuclear or nuclear regions of fetal and adult cardiac myocytes.5,12 TNNI3K has a full-length cDNA with 3,420 base pairs (bp) and contains a continuous open reading frame of 2,505 bp, which encodes a protein of 835 amino acids and a molecular mass of 93 kDa.10

TNNI3K contains a central kinase domain, flanked by an ankyrin repeat domain in the amino terminus and a serine-rich domain in the C-terminus (Figure 2). BLAST analysis of TNNI3K sequence identifies integrin-linked kinase (ILK), a 4-ankyrin-repeat kinase, as its closest relative. ILK is a highly evolutionarily conserved intracellular protein that was originally identified as an integrin-interacting protein. It plays a vital role in embryonic development and tissue homeostasis.14,15 Importantly, ILK also has central roles in cardiac and smooth-muscle contractility, and ILK dysregulation causes cardiomyopathies in humans.13,16 The kinase domain of TNNI3K contains primary sequence motifs conserved in both serine/threonine and tyrosine protein kinases. This assigns TNNI3K to a family of protein kinases, the mixed lineage kinase family.

Mechanism of Cardiac-Specific Expression

Wang et al13 cloned the full-length mRNA sequence and characterized the basal promoter region of the mouse TNNI3K gene. By using a bioinformatics approach, 5 potential conserved transcription factor binding sites were identified in the core promoter region of the mouse TNNI3K gene. These include Tbx5, SRE, M-CAT box, MEF2 and GATA4. MEF2C plays a critical role in regulating TNNI3K transcriptional activity, because mutations in MEF2 binding sites caused a drastic decrease in transcriptional activity.13 MEF2C transcripts are largely restricted to the cardiac and skeletal muscle lineages.17,18 In mice homozygous for a null mutation of MEF2C, heart development arrests at the looping stage, the right ventricle does not form, and a subset of cardiac muscle genes are not expressed, suggesting that MEF2C is an essential regulator of cardiac myogenesis and right ventricular development.19 In the adult heart, overexpression of MEF2 induces dilated cardiomyopathy in transgenic mice and activates a genetic program promoting left ventricular (LV) chamber dilatation and mechanical dysfunction in a heart failure model.20,21 Thus, considering the known function of MEF2 family members in cardiac development and disease processes, it is not surprising that the cardiac-enriched transcription factor MeF2c is the most critical for cardiac-specific expression of TNNI3K.

<p>| Table. List of TNNI3K Loss-of-Function and Gain-of-Function Studies With Genetically Modified Animal Models |</p>
<table>
<thead>
<tr>
<th>SN</th>
<th>Genetic model</th>
<th>HF model</th>
<th>Phenotype/outcome</th>
<th>Mechanism/characteristic</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cardiac specific-TG</td>
<td>IR</td>
<td>Detrimental</td>
<td>p38 activation, Mitochondrial dysfunction, ROS overproduction, impaired cardiomyocytes bioenergetics</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>Cardiac specific-KO</td>
<td>IR</td>
<td>Protective</td>
<td>Reduced p38 activation, ROS production and cardiomyocyte death</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>Cardiac-specific TG</td>
<td>–</td>
<td>Physiological hypertrophy</td>
<td>Increased heart mass with enhanced cardiac function, no necrosis or apoptosis</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>Cardiac-specific TG</td>
<td>TAC</td>
<td>Detrimental</td>
<td>Cardiac remodeling, increased expression of ANP and BNP</td>
<td>9</td>
</tr>
<tr>
<td>5</td>
<td>Cardiac-specific kinase-dead TG</td>
<td>TAC</td>
<td>Protective</td>
<td>Attenuated remodeling, decreased expression of ANP and BNP</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>Intramyocardial injection of TNNI3K-overexpressing P19C16 cells</td>
<td>MI</td>
<td>Protective</td>
<td>Improved LV function and remodeling post-MI</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>Double TG of TNNI3K and calsequestrin</td>
<td>Cardiomyopathy</td>
<td>Detrimental</td>
<td>Severely impaired systolic function and increased mortality</td>
<td>11</td>
</tr>
</tbody>
</table>

ANP, atrial natriuretic protein; BNP, B-type natriuretic peptide; HF, heart failure; IR, ischemia-reperfusion; KO, knock-out; LV, left ventricular; MI, myocardial infarction; ROS, reactive oxygen species; TAC, transverse aortic constriction; TG, transgenic.
**Figure 2.** Schematic of TNNI3K structure shows 3 distinct domains. The N-terminal ankyrin repeat, a central kinase domain and the serine-rich domain at the C-terminal. It shares a domain structure similar to that of ILK. ANK, ankyrin; Ser-rich, serine-rich; ILK, integrin-linked kinase.

**TNNI3K Binding Partners**

TNNI3K was named on the basis of its interaction with cardiac troponin I (cTnI).\(^\text{1,2}\) A yeast 2-hybrid screen using TNNI3K as bait identified cTnI as an interacting protein and, therefore, a possible substrate. Feng et al identified peroxiredoxin 3 (PRDX3; previously named antioxidant protein 1) as another TNNI3K interacting partner.\(^\text{2,3}\) PRDX3 belongs to a thiol-specific antioxidant protein family.\(^\text{2,3,4}\) and interacts with TNNI3K to downregulate its kinase activity.\(^\text{2,2}\) A yeast 2-hybrid screen and an in-vitro binding assay confirmed a direct interaction of PRDX3 and TNNI3K. Studies with deletion mutants of TNNI3K demonstrated that PRDX3 could not only bind to the ankyrin motif but also to the protein kinase domain of TNNI3K, suggesting that PRDX3 exerts its inhibitory effect through its interaction with the protein kinase domain of TNNI3K. Studies with deletion mutants of PRDX3 demonstrated that the binding site located within the C-terminal 60–256 amino acids of PRDX3; that is, the thiol-specific antioxidant domain. Further studies are warranted to determine the molecular details and physiological significance of the PRDX3 and TNNI3K interaction in-vivo. Several other potential TNNI3K interacting partners have been proposed, which includes fatty acid binding proteins 3, aryl hydrocarbon receptor-interacting protein, adult skeletal muscle actin and cardiac myosin binding protein C.\(^\text{5,10,12}\) However, further investigation is required to confirm these potential interactions and their biological significance.

**TNNI3K as a Potential Target of Cardiac Remodeling**

**Role of TNNI3K in Cardiomyopathy and MI-Induced Remodeling**

Initial in vitro studies suggested a protective role of TNNI3K in cell death, as its overexpression led to an increased beating mass, which was associated with reduced apoptosis.\(^\text{10}\) That study utilized pluripotent P19CL6 cells with or without transfection by pcDNA6-TNNI3K plasmid to determine TNNI3K’s role in cardiac myogenesis. Those authors concluded that TNNI3K promotes the differentiation process based on the increased beating mass and number of α-actinin-positive cells after TNNI3K overexpression. Intramyocardial administration of TNNI3K-overexpressing P19CL6 cells in mice post-MI improved cardiac performance and attenuated ventricular remodeling compared with injection of wild-type P19CL6 cells. Thus, early data suggest that TNNI3K has a protective role after myocardial injury.

However, several high profile studies with genetically modified animals challenged the protective role of TNNI3K in cardiac disease processes and strongly suggested that activation of TNNI3K leads to a detrimental phenotype and conversely its inhibition leads to significant protection both at baseline and post-injury.\(^\text{6,7,8,11}\) Wheeler et al\(^\text{11}\) demonstrated that both normal expression and TNNI3K overexpression had a detrimental effect on cardiac function. This was demonstrated by utilizing different inbred and congenic mouse strains, which have significant heterogeneity in the expression level of endogenous TNNI3K. Interestingly, some strains are natural loss-of-function models because they harbor 100-fold less TNNI3K expression than others. Mice not expressing TNNI3K were resistant to calsequestrin-induced cardiomyopathy, whereas normal or high expressers were highly susceptible to 2 different models of heart failure. TNNI3K overexpression greatly accelerates cardiac dysfunction in mouse models of cardiomyopathy, indicating an important role of TNNI3K in modulating cardiac disease progression.\(^\text{11}\)

By using cardiac-specific TNNI3K transgenic, conditional KO, and novel pharmacological inhibitors, we demonstrated that TNNI3K plays an important role in the development of IR injury and thus its inhibition could be a novel drug target to treat myocardial IR injury. Genetic overexpression of TNNI3K leads to larger infarcts in comparison with wild-type littermates after IR injury. Consistently, TNNI3K transgenic mice have elevated plasma levels of cTnI. Kinase activity of TNNI3K was responsible for the larger infarct size, because kinase-dead transgenic mice had significantly smaller infarcts and reduced plasma cTnI levels. Surprisingly, we found that TNNI3K regulates several essential functions of mitochondrial biology including mitochondrial reactive oxygen species production (mROS), mitochondrial membrane potential and mitochondrial calcium flux. Thus, TNNI3K-dependent cell death and IR-induced cardiac dysfunction are mediated through overproduction of mROS and subsequent mitochondrial impairment. Furthermore, we identified p38αMAPK as a key downstream effector of TNNI3K that is, in part, responsible for its detrimental effect (Figure 3). Consistent with the gain-of-function model, cardiomyocyte-specific deletion of
TNNI3K: Emerging Drug Target for CVD

Physiological and Pathological Hypertrophy

Pathological cardiac hypertrophy is associated with increased interstitial fibrosis, cell death and cardiac dysfunction, and is a key risk factor for heart failure. Wheeler et al.\textsuperscript{11} were the first to demonstrate that overexpression of TNNI3K accelerates disease progression in a pressure-overload-induced model of pathological hypertrophy. The TNNI3K transgenic mice showed increased adverse dilative remodeling in response to thoracic aortic constriction (TAC) surgery, as reflected by increased LV end-diastolic diameter and LV end-systolic diameter. This dilative remodeling was associated with a reduction of ventricular function as reflected by reduced fractional shortening, confirming that TNNI3K expression has a detrimental effect in a model of pathological hypertrophy.\textsuperscript{6}

To begin to translate these preclinical observations to the clinic, we developed 2 small-molecule TNNI3K inhibitors and tested their efficacy in a myocardial IR model in-vivo. Pharmacological inhibition of TNNI3K reduced mROS, p38 activation, and infarct size when delivered at reperfusion to mimic clinical intervention. Treatment with TNNI3K inhibitor also limited chronic adverse remodeling and preserved cardiac function in the reperfused heart.\textsuperscript{6} Thus, taken together our recent preclinical studies indicate that TNNI3K inhibition could represent a therapeutic strategy for acute coronary syndromes. This hypothesis is being tested in studies to be done via the CAESAR Program.

Figure 3. Molecular signaling mechanism of TNNI3K in response to cardiac injury. After cardiac injury, TNNI3K induces p38 phosphorylation by an unknown mechanism. Activation of p38 results in increased mitochondrial reactive oxygen species (ROS) generation, resulting in cell death that leads to increased infarct size and adverse ventricular remodeling. The role of TNNI3K-dependent mitochondrial dysfunction or oxidative stress in the development of cardiac hypertrophy is unknown. Overexpression studies have suggested that TNNI3K also increases the velocity of diastolic depolarization (VDD) of phase 4 of the spontaneous action potential through suppression of the phosphorylation of cTnI, resulting in increased contractile force. TNNI3K may increase the contractile force by modulating the ryanodine receptor-mediated intracellular Ca\textsuperscript{2+} concentration. cTnI, cardiac troponin I; I/R, ischemia-reperfusion injury; MI, myocardial infarction; RyR, ryanodine receptor; SR, sarcoplasmic reticulum; TAC, transverse aortic constriction.
TNNI3K-mediated pathological hypertrophy. Transverse aortic constriction-induced hypertrophic responses were significantly attenuated in the transgenic kinase-dead mice, confirming that TNNI3K kinase activity plays an essential role in pro-hypertrophic responses driven by biomechanical stress-induced pathologic cardiac hypertrophy.

TNNI3K has also been implicated in physiological cardiac hypertrophy.6 In contrast to pathological hypertrophy, physiological cardiac hypertrophy is reversible and characterized by normal cardiac morphology (ie, no fibrosis or apoptosis) and enhanced cardiac function. Wang et al10 reported that TNNI3K transgenic mice develop a phenotype of concentric hypertrophy with enhanced cardiac function, as revealed by echocardiography and hemodynamic assessments. They concluded it was physiological hypertrophy because neither necrosis nor myocyte apoptosis was observed in the heart of TNNI3K transgenic mice. However, we did not observe physiological or pathological hypertrophy in TNNI3K transgenic or KO mice at baseline. Taken together, the available evidence suggests that TNNI3K plays an important role in mediating pathological hypertrophy; however, its role in physiological hypertrophy needs further confirmation.

Role of TNNI3K in Viral Myocarditis
Myocarditis is an inflammatory disease of the heart, frequently resulting from viral infections and/or subsequent immune response. Evidence of viral infection as a cause of heart failure has been recognized for >50 years, but it is still a challenging disease to diagnose and treat.26,27 Several viruses have been associated with myocarditis in humans, and of those identified, adenovirus, enterovirus and cytomegalovirus are the most common. However, coxsackievirus B3 is still considered the dominant etiological agent.28 In a multicenter analysis of 624 patients in the United States with histologically-proven myocarditis, the presence of various virus genomes was confirmed in 239 of biopsy samples (38%).26 At present, no diagnostic gold standard is available for viral myocarditis; however, even after proper diagnosis, management of viral myocarditis represents a difficult challenge because there is no clinically proven treatment to inhibit the development of subsequent dilated cardiomyopathy.27,28 This is primarily because of a lack of known molecular drug candidates for viral myocarditis susceptibility.31 Wiltshire et al32 identified TNNI3K as a candidate gene for viral myocarditis in an unbiased screen based on quantitative trait locus analysis, pathway analysis and consomic mapping. A combination of analyses revealed very strong evidence for the existence and location of viral myocarditis susceptibility 1 (Vms1) locus on chromosome 3. Further microarray and candidate gene analysis identified TNNI3K as a likely candidate for Vms1. Further study is warranted to investigate the pathophysiology and mechanistic details of this association.

Role of TNNI3K in Cardiac Conduction
Atrioventricular (AV) conduction disease is characterized by a prolonged PR interval on the surface electrocardiogram. Importantly, a prolonged PR interval is a strong predictor of atrial fibrillation (AF). AF is the most commonly observed arrhythmia and is associated with an increased risk of stroke, heart failure, and sudden cardiac death. The association of TNNI3K and cardiac conduction was first observed in a microarray screening of human failing heart samples from patients with arrhythmogenic right ventricular cardiomyopathy.33 Arrhythmogenic cardiomyopathy was associated with upregulation of TNNI3K, regardless of cardiomyopathic etiology. Further regression analysis showed a positive correlation between TNNI3K and ProANP in arrhythmogenic failing hearts.33 Recently, Lodder et al34 provided strong evidence that increased expression of TNNI3K is significantly correlated with increased PR interval. Measurement of the PR interval and TNNI3K levels in 6 inbred mice lines identified a positive correlation between them.34 In the same study, the investigators performed in-vivo functional studies using TNNI3K transgenic mice to confirm its role in regulating PR interval in AV conduction.34,35 The molecular mechanism underlying TNNI3K-mediated AV conduction is unknown and requires further indepth investigation.

Role of TNNI3K in Obesity
Several recent human genetic studies with diverse populations have suggested an important role of TNNI3K in regulation of body mass index (BMI) and the development of obesity.36–38 Zhao et al were the first to find an association between common childhood obesity and a single-nucleotide polymorphism in TNNI3K in a study of European Americans, aged between 2 and 18 years old.39 Subsequently, observation from the Look AHEAD trial suggested a significant association of risk allele at TNNI3K with lower percentage of energy from protein sources.38 A genome-wide association study (GWAS) analysis of BMI in adolescents and young adults reveals that TNNI3K had a larger effect on BMI during adolescence and young adulthood compared with older adults.37 Another recent GWAS suggests that TNNI3K is positively associated with emotional and uncontrolled eating.36 Thus, although a strong correlation between TNNI3K and obesity has been indicated by population-based genetic studies, the mechanistic basis of this association is unknown and needs further investigation.

Conclusions and Future Perspectives
Infarct size is a major determinant of cardiac remodeling. To date, multiple experimental interventions have been reported to protect the ischemic myocardium in experimental animals. Unfortunately, with the exception of timely reperfusion, none have translated into clinical practice. As most of these therapeutic interventions are based on targeting ubiquitously expressed kinases, one can speculate that harmful side-effects could arise from systemic administration of 1 or more compounds that modulate kinase activity. Our recent findings that TNNI3K inhibition can limit infarct size and adverse cardiac remodeling after IR injury is especially promising, because TNNI3K inhibition would be cardiac-specific, and thus limit the adverse effects of systemic kinase inhibition. However, in order to provide effective translation of TNNI3K inhibition and cardioprotection in the clinical setting, it is fundamental to first understand, in preclinical animal models, not only the pharmacokinetics but also the signaling pathways involved. Further investigation of TNNI3K binding partners and downstream targets would bring clarity to TNNI3K-mediated cellular responses in the contexts of interest. Defining the molecular link between TNNI3K and the immune response to viral pathogens may reveal new principles for the management of viral myocarditis. Several GWAS analysis have suggested that TNNI3K may regulate insulin resistance and obesity, but further investigation is warranted to establish this link. Finally, by unraveling the molecular details of TNNI3K biology, identifying binding partners and downstream targets, and establishing their roles in various aspect of cardiac biology, would benefit the field tremendously. Finally, another patient population that has a profound unmet therapeutic need
is the one with frequent and recurrent ischemic events, but they are not candidates for surgery. The development of enhanced TNNI3K inhibitor-based therapeutics could protect these patients from the common scenario of gradually declining contractile function.

Acknowledgments

This work was supported by grants from the NHLBI to T. Force (HL061688, HL091799) and American Heart Association Scientist Development Grant (13SDG16930103) to H.L.

Disclosures
Dr Force received research funding, as well as consultancy fees from GlaxoSmithKline.

References